Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Pentosidine - a new biochemical marker in diabetic retinopathy.

Salman AG, Mansour DE, Swelem AH, Al-Zawahary WM, Radwan AA.

Ophthalmic Res. 2009;42(2):96-8. doi: 10.1159/000225661. Epub 2009 Jun 18.

PMID:
19546600
2.

Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.

Ghanem AA, Elewa A, Arafa LF.

Eur J Ophthalmol. 2011 Jan-Feb;21(1):48-54.

PMID:
20544678
3.

Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.

Miura J, Yamagishi Si, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y.

J Diabetes Complications. 2003 Jan-Feb;17(1):16-21.

PMID:
12505751
5.

Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.

Kerkeni M, Saïdi A, Bouzidi H, Ben Yahya S, Hammami M.

Microvasc Res. 2012 Nov;84(3):378-83. doi: 10.1016/j.mvr.2012.07.006. Epub 2012 Jul 24.

PMID:
22835520
6.

Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.

Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M.

Diab Vasc Dis Res. 2013 May;10(3):239-45. doi: 10.1177/1479164112460253. Epub 2012 Oct 22.

PMID:
23091285
7.

Correlation between plasma pentosidine concentrations and retinal hemodynamics in patients with type 2 diabetes.

Sato E, Nagaoka T, Yokota H, Takahashi A, Yoshida A.

Am J Ophthalmol. 2012 May;153(5):903-909.e1. doi: 10.1016/j.ajo.2011.10.020. Epub 2012 Jan 21.

PMID:
22265156
8.

Skin collagen pentosidine and fluorescence in diabetes were predictors of retinopathy progression and creatininemia increase already 6years after punch-biopsy.

Sternberg M, M'bemba J, Urios P, Borsos AM, Selam JL, Peyroux J, Slama G.

Clin Biochem. 2016 Feb;49(3):225-31. doi: 10.1016/j.clinbiochem.2015.10.011. Epub 2015 Oct 24.

PMID:
26506116
9.

Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.

Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Van Ypersele de Strihou C, Kurokawa K.

J Am Soc Nephrol. 1998 Sep;9(9):1681-8.

10.
11.

Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy.

Ng ZX, Chua KH, Iqbal T, Kuppusamy UR.

Int J Mol Sci. 2013 Apr 3;14(4):7480-91. doi: 10.3390/ijms14047480.

12.

Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy.

Daimon M, Ono Y, Saito T, Yamaguchi H, Hirata A, Ohnuma H, Igarashi M, Eguchi H, Manaka H, Kato T.

Diabetes Care. 1999 May;22(5):877-8. No abstract available.

13.

Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy.

Nakamura N, Hasegawa G, Obayashi H, Yamazaki M, Ogata M, Nakano K, Yoshikawa T, Watanabe A, Kinoshita S, Fujinami A, Ohta M, Imamura Y, Ikeda T.

Diabetes Res Clin Pract. 2003 Aug;61(2):93-101.

PMID:
12951277
14.

Pentosidine plasma levels and relation with metabolic control in diabetic patients.

Lapolla A, Reitano R, Baccarin L, Sartore G, Plebani M, Fedele D.

Horm Metab Res. 2005 Apr;37(4):252-6.

PMID:
15952087
15.

Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy.

Aso Y, Takanashi K, Sekine K, Yoshida N, Takebayashi K, Yoshihara K, Inukai T.

J Lab Clin Med. 2004 Aug;144(2):92-9.

PMID:
15322503
16.

Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.

Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ.

J Clin Invest. 1993 Jul;92(1):212-7.

17.

Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).

Schiel R, Franke S, Appel T, Voigt U, Ross IS, Kientsch-Engel R, Stein G, Müller UA.

J Diabetes Complications. 2003 Mar-Apr;17(2):90-7.

PMID:
12614975
19.

Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.

Kanazawa I, Yamamoto M, Yamaguchi T, Sugimoto T.

Exp Clin Endocrinol Diabetes. 2011 Jun;119(6):362-5. doi: 10.1055/s-0030-1267953. Epub 2011 Apr 6.

PMID:
21472665
20.

Plasma advanced glycosylation end-products in maintenance haemodialysis patients.

Odetti P, Cosso L, Pronzato MA, Dapino D, Gurreri G.

Nephrol Dial Transplant. 1995 Nov;10(11):2110-3.

PMID:
8643178

Supplemental Content

Support Center